Columbus CyberKnife: Treat Prostate Cancer in 5 Treatments

Watch Douglas W. Widman, M.D., Medical Director at Columbus CyberKnife, and Thomas, a CyberKnife patient, talk about how CyberKnife is an excellent treatment option for prostate cancer. CyberKnife is as effective as surgery and is completed in only 5 outpatient treatment sessions compared to the 44 you have with traditional radiation therapy. In addition, CyberKnife treatment is painless, there are minimal (if any) side effects, and there is no disruption to your daily life.

The Importance of Getting a Second Opinion

A recent article from CancerConnect.com, a patient-focused cancer website, suggests that if you have been diagnosed with cancer, seeking a second opinion will allow you to learn more about your cancer type and make truly informed decisions about treatment.

The article recommends that all cancer patients should consider seeing at least one additional expert after an initial diagnosis.  Getting a second opinion is an important part of becoming educated about a cancer diagnosis and treatment options and will also give you the opportunity to find a physician you are comfortable with, someone you respect and who you believe is paying attention to your needs.

In the article, the following questions are addressed:

What Is a Second Opinion?

Why Do I Need a Second Opinion?

Is Getting a Second Opinion Considered “Bad Etiquette”?

Who Pays for A Second Opinion?

Where Should I Get a Second Opinion?

Who Should Get a Second Opinion?

In addition to the questions above, the article also covers tips for preparing for your second opinion appointment, including writing questions down ahead of time and bringing someone with you to help listen and understand the information discussed.

It is an extremely informative article and one that Columbus CyberKnife strongly advocates patients read.

If you, or a loved one, have recently been diagnosed with cancer and you would like information on treatment options, or a second opinion, please do not hesitate to contact a member of our team today.

SBRT Offers Prostate Cancer Patients High Cancer Control and Low Toxicity in Fewer Treatments

According to research presented at the recent 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO), high dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates.   

Although prostate tumors generally respond well to radiation therapy (RT), the possibility of radiation exposure to healthy tissue in the genitourinary (GU) and gastrointestinal (GI) systems can be of concern. SBRT is an advanced technique that precisely targets high doses of RT to the tumor in a small number fractions, simultaneously avoiding surrounding tissue and reducing toxicity to non-cancerous cells.  The technique has become the standard of care for many non-surgical lung cancer patients, as it limits exposure to the heart and surrounding lungs.  When treating tumors in the prostate, SBRT avoids the adjacent bladder, sex organs and rectum. 

For the study, which was the first large multi-institutional study of SBRT in prostate cancer with long-term follow-up, a total of 309 men with newly diagnosed prostate cancer were enrolled in the trial at 21 community, regional, and academic hospitals across the U.S.  Eligible patients had either low-risk disease or intermediate-risk disease and all of the men received SBRT.  At five years following SBRT, 97 percent of patients were free from prostate cancer progression and fewer than two percent of all patients experienced serious side effects. 

“Our results illustrate how advanced technology has radically improved our ability to target cancer,” said Robert Meier, M.D., lead author of the study and a radiation oncologist at Swedish Medical Center in Seattle.  “After following patients for more than five years, we found that serious side effects from a brief course of SBRT were uncommon and that cancer control rates were very favorable compared to historical data. Our trial confirms that SBRT may be preferable to other treatment approaches for newly-diagnosed cases of prostate cancer, including more aggressive disease.” 

At Columbus CyberKnife, men diagnosed with prostate cancer are treated with SBRT with the CyberKnife® Robotic Radiosurgery System.  CyberKnife is a painless, nonsurgical prostate cancer treatment technology in which high-dose radiation is delivered to the tumor from a linear accelerator mounted on a highly maneuverable robotic arm.  Hundreds of different angles enable the radiation to be contoured to the shape of the prostate, resulting in treatment aimed directly to the prostate gland, avoiding nearby critical anatomy.  This precision reduces treatment time to just five outpatient visits, compared to the average 40 – 45 visits conventional radiation therapy requires. 

To learn more about how Columbus CyberKnife treats prostate cancer, please click here

Stereotactic Body Radiation Therapy Shows 98 Percent Prostate Cancer Cure

According to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, a five-year study shows that stereotactic body radiation therapy (SBRT) offers a higher cure rate for prostate cancer than more traditional approaches. 

The study, the first trial to publish five-year results from SBRT treatment for prostate cancer, found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.  It is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue. 

Raquibul Hannan, M.D., Ph.D., lead author for the study said, “The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment.  What we now have is a more potent and effective form of completely noninvasive treatment for prostate cancer, conveniently completed in five treatments.” 

The study’s senior author Robert Timmerman, M.D., added, “The current form of radiation is 44 treatments given over nine weeks.  In contrast, the SBRT therapy we used allows the delivery of highly focused radiation in only five treatments, allowing patients to return to their normal lives more quickly.  SBRT is both more convenient and has increased potency.” 

At Columbus CyberKnife, men diagnosed with prostate cancer are treated with SBRT with the CyberKnife® Robotic Radiosurgery System.  CyberKnife is a painless, nonsurgical prostate cancer treatment technology in which high-dose radiation is delivered to the tumor from a linear accelerator mounted on a highly maneuverable robotic arm.  Hundreds of different angles enable the radiation to be contoured to the shape of the prostate, resulting in treatment aimed directly to the prostate gland, avoiding nearby critical anatomy.  This precision reduces treatment time to just five outpatient visits, compared to the average 40 – 45 visits conventional radiation therapy requires. 

To learn more about how Columbus CyberKnife treats prostate cancer, including a video on prostate cancer treatment, please click here

Prostate Cancer Treated More Aggressively in the City

According to a recent study published in the journal Prostate Cancer and Prostatic Diseases, urban men with localized prostate cancer may be more likely to get surgery or radiation than their rural peers. 

Men had 23 percent higher odds of getting these aggressive treatments when they lived in densely populated U.S. counties than if they resided in rural counties, according to the analysis of cancer registry data for about 138,000 men.  The conservative alternatives, watchful waiting or hormone therapy to shrink tumors without surgery or radiation, were more common in less populated areas, with 22 percent of rural men receiving this type of care compared with 19 percent of their urban counterparts. 

Cancer care requires sophisticated resources, including medical, surgical, and radiation therapy specialists.  These specialists are less likely to be found in rural areas, especially small and isolated small rural areas, as their work can require specialized consultative care, found primarily in urban areas and rural areas with sizeable populations. 

Dr. Clint Cary, a urology researcher at the Indiana University School of Medicine in Indianapolis and lead author of the study said, “Men in urban areas have access to more physicians in addition to more advanced technology on both the surgical and radiation therapy front.  Smaller hospitals in rural areas will likely not be able to fund the expense of robotic surgical equipment, intensely modulated radiation therapy or proton beam radiation centers.” 

At Columbus CyberKnife, men diagnosed with prostate cancer are treated with the latest state-of-the-art cancer technology, the CyberKnife® Robotic Radiosurgery System.  CyberKnife is a painless, nonsurgical prostate cancer treatment in which high-dose radiation is delivered to the tumor from a linear accelerator mounted on a highly maneuverable robotic arm.  Hundreds of different angles enable the radiation to be contoured to the shape of the prostate, resulting in treatment aimed directly to the prostate gland, avoiding nearby critical anatomy.  This precision reduces treatment time to just five outpatient visits, compared to the average 45 visits conventional radiation therapy requires.  

Columbus CyberKnife proudly serves the greater Columbus area and surrounding communities.  We have had patients drive over a 100 miles for our services.  We understand that your time is important and we are here to try to help you keep to your normal day-to-day routine during your treatment.  Since CyberKnife treats prostate cancer in just five visits, you will be done with your cancer treatment in less than two weeks.  

For more information on Columbus CyberKnife, including where we are located and how to make an appointment, please click here

September is National Prostate Cancer Awareness Month

National Prostate Cancer Awareness Month is observed every September in the United States by health experts and advocates, and individuals concerned with men’s prostate health.  Designating a month for the disease serves the purpose of increasing public awareness of the importance of prostate health and screenings, educating about risk factors and symptoms, and advocating for further research on prostate health issues.

Prostate cancer is the second most common cancer in American men.  About one in nine men will be diagnosed with prostate cancer during his lifetime.  According to the American Cancer Society, there will be about 174,650 new cases of prostate cancer diagnosed (over 5,300 in Ohio) and about 31,620 deaths from prostate cancer in the United States during the year 2019.

There are several risk factors associated with prostate cancer, including family history, race, and diet, but the most common factor is age. Prostate cancer occurs mainly in older men.  About six in ten cases are diagnosed in men aged 65 or older, and it is rare before age 40.  The average age at the time of diagnosis is about 66.

While there are a lot of risk factors for prostate cancer, there are also good survival statistics associated with the disease.  Survival rates for prostate cancer are very high.  More than 2.9 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.

At Columbus CyberKnife, men diagnosed with prostate cancer are treated with the CyberKnife® Robotic Radiosurgery System.  CyberKnife is a painless, non-invasive prostate cancer treatment technology in which high-dose radiation is delivered to the tumor from a linear accelerator mounted on a highly maneuverable robotic arm.  Hundreds of different angles enable the radiation to be contoured to the shape of the prostate, resulting in treatment aimed directly to the prostate gland, avoiding nearby critical anatomy.  This precision reduces treatment time to just five outpatient visits, compared to the average 45 visits conventional radiation therapy requires.

To learn more about prostate cancer, please visit the Prostate Cancer Foundation at www.pcf.org.  To find out more about how Columbus CyberKnife treats prostate cancer, please click here.

The National Comprehensive Cancer Network® Supports SBRT for Prostate Cancer

The National Comprehensive Cancer Network recently updated their patient guide that supports stereotactic body radiation therapy (SBRT) for prostate cancer. 

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 26 of the world’s leading cancer centers, is dedicated to improving the quality, efficiency, and effectiveness of care for patients with cancer.  

NCCN aims to provide people with cancer and the general public with state-of-the-art cancer treatment information in easy-to-understand language.  The NCCN Guidelines for Patients®, translations of the NCCN clinical guidelines, are meant to help patients with cancer talk with their physicians about the best treatment options for their disease. 

The NCCN guidelines for patients now states “Stereotactic body radiotherapy (SBRT, for short) has been added as an option to be carefully decided.  If chosen, it should be received at cancer centers with the proper equipment and experience.” 

At Columbus CyberKnife, our physician team and staff have extensive experience treating patients with stereotactic radiation therapy.  Prostate cancer patients are treated with SBRT using the CyberKnife® Robotic Radiosurgery System.  CyberKnife is a powerful, noninvasive treatment system that precisely focuses radiation to match the size and shape of a patient’s prostate cancer, minimizing damage to surrounding tissue. 

For more information on NCCN’s Guidelines for Patients, please click here.  To learn more about the benefits of CyberKnife treatment, or to find out if you are a candidate, click here.